A Phase I/Ib Study of the CDK Inhibitor Dinaciclib in CLL

Video

John C. Byrd, MD, from OSUCCC – James, describes a phase I/Ib trial looking at dinaciclib for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

Clinical Pearls

John C. Byrd, MD, director of the division of hematology and a CLL specialist at the Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), describes a phase I/Ib trial looking at dinaciclib for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

  • Dinaciclib is a second-generation selective inhibitor of CDKs 1, 2, 5, and 9
  • This agent was evaluated in a phase I/Ib expansion study in patients with relapsed or refractory CLL
  • Unlike early CDK inhibitors, dinaciclib induced a high response rate (65-70%) and durable remissions
Related Videos
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Jamie Koprivnikar, MD, and Hana Safah, MD, experts on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Related Content